SCYX - SCYNEXIS INC

0.9858
-0.014   -1.440%

Share volume: 265,745
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$1.00
-0.01
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 18%
Dept financing 18%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.35%
1 Month
24.83%
3 Months
33.13%
6 Months
43.51%
1 Year
-0.42%
2 Year
-45.84%
Key data
Stock price
$0.99
P/E Ratio 
N/A
DAY RANGE
$0.97 - $1.00
EPS 
-$0.17
52 WEEK RANGE
$0.56 - $1.31
52 WEEK CHANGE
-$0.21
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
44.664 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$378,376
AVERAGE 30 VOLUME 
$1,007,875
Company detail
CEO: Marco Taglietti
Region: US
Website: scynexis.com
Employees: 60
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm, CJSC.

Recent news